Professor Sunil Lakhani was elected to the BCT Board of Directors in July 2017 and was appointed Chair of the Board in September 2021. He is the Executive Director of Research and Senior Staff Specialist at Pathology Queensland and Head of the Breast Group, Centre for Clinical Research, University of Queensland, Brisbane, Australia. He is a clinical diagnostic pathologist and also heads a research team comprising scientists and clinicians, ensuring a translational focus to the program. His current research interests include lobular carcinoma and its variants, basal-like breast cancers and mechanisms and therapeutic developments of brain and distant metastases. He was Series Editor of the 4th Edition WHO Tumour Classification Monographs and Volume Editor of the WHO 4th Ed Tumours of the Breast (2012) and standing member of the Board for the WHO 5th Edition (2017-2021). He is the recipient of the Distinguished Pathologist Medal, International Academy of Pathology (2015); the BCT’s Robert Sutherland Award for Excellence in Translational Research (2016); The Distinguished Fellow Award, The Royal College of Pathologists of Australasia (2017) and The William L. Gerald Award, Memorial Sloane Kettering Cancer Center, New York USA (2021). In 2017, he was elected Fellow of the Australian Academy of Health and Medical Sciences.

Mr Luke Bugden was appointed to the BCT Board of Directors in October 2019 and was appointed to Chair of the Finance, Risk and Audit Committee in September 2021. Mr Bugden is a Partner of professional services firm PricewaterhouseCoopers (PwC), with over 21 years of experience providing advice to a wide range of public and private entities in a number of different sectors including, infrastructure, manufacturing, utilities, financial services, services, not-for-profit and pharmaceutical. He also worked in the New York office of PwC where he advised a number of foreign investors investing into Australia. Mr Bugden has extensive experience advising clients on a range of issues including capital management opportunities, financing arrangements and corporate governance. He holds a Bachelor of Commerce (Accounting and Finance) and is a member of the Chartered Accountants of Australia and New Zealand (CA).

Dr Richard Isaacs MNZM was elected to the BCT Board of Directors in July 2014. Dr Isaacs is a Medical Oncologist and was Head of Medical Oncology at Palmerston North Hospital, New Zealand from 2011 until 2021. He has been an investigator on multiple clinical trials. Dr Isaacs was Vice President of the Palmerston North Medical Research Foundation from 2008-2013 and Chair of the New Zealand Breast Cancer Specialist Interest Group from 2008-2011. He was Chair of the New Zealand Specialist Advisory Committee for the Royal Australasian College of Physicians from 2010-2013. He now sits on the Cancer Treatments Subspecialty Advisory Group to Pharmac. In 2009, Dr Isaacs was awarded an MNZM for services to oncology.

Professor Sherene Loi was elected to the BCT Board of Directors in July 2020. She is a member of the BCT Scientific Advisory Committee. Professor Loi is a Medical Oncologist specialising in breast cancer treatment as well as a clinician scientist with expertise in genomics, immunology and drug development. She is the Head of the Translational Breast Cancer Genomics and Therapeutics laboratory at the Peter MacCallum Cancer Centre, Melbourne, as well as Consultant Medical Oncologist in the Breast Service and head of the Breast Cancer Clinical Trials Unit. As a result of her research, Professor Loi has led a number of international breast cancer clinical trials in immunotherapy. She has published over 270 peer-reviewed research articles with a lifetime H index of 94 and recent work has been highly influential with 44,000 total citations, 73% within the past 5 years (Google Scholar). Professor Loi Co-Chairs the Scientific Executive Committee and the Translational Working Group of the International Breast Cancer Study Group (IBCSG) based in Bern, Switzerland which conducts academic global breast cancer clinical trials in over 16 countries. She is the current holder of the Inaugural National Breast Cancer Foundation (NBCF) of Australia Endowed Chair and is a research fellow of the Breast Cancer Research Foundation (BCRF), New York and received the Prime Ministers’ Awards for Science in 2021.

Professor Bruce Mann was elected to the BCT Board of Directors in July 2015 and was appointed Chair in July 2017. He stepped down from his role on the Board after he was appointed to the position of Director of Research in August 2021. He is the Chair of the BCT Scientific Advisory Committee. Professor Mann is Director of the Breast Tumour Stream of the Victorian Comprehensive Cancer Centre, and works at Royal Melbourne, Royal Women’s Hospital and the Peter MacCallum Cancer Centre. He is active in clinical and translational breast cancer research. Professor Mann is a member of the Australian Institute of Company Directors (MAICD) and is also on the board of the Breast Cancer Network of Australia.

Ms Fiona McPhee was appointed to the BCT Board of Directors in October 2019 and is a member of the Communications and Fundraising Committee. Fiona is a leading fundraising consultant who works with non-profit leaders around the globe. She has been a senior strategist in one of Australasia’s leading fundraising agencies for well over a decade, responsible for the market’s leading fundraising benchmarking program. Fiona’s mission is to inspire boards and organisational leadership teams through a research and evidence based approach to ‘Great Fundraising’. She is a sought after coach and mentor to fundraising teams and leaders. Before devoting her time to the non-profit sector Fiona was a sales and marketing executive. Fiona sits on several non-profit boards, is the Australian & New Zealand Ambassador to the Resource Alliance, and is an advisor to several commercial businesses providing services to the non-profit industry. Fiona has written for Fundraising & Philanthropy magazine, FINZ magazine and a variety of fundraising and marketing blogs. She presents regularly on a variety of fundraising topics and has presented most recently at International Fundraising Congress (IFC) Netherlands, FIA national conference, FINZ national conference and the Fundraising & Philanthropy Forum.

Ms Marg O’Donnell AO was appointed to the BCT Board of Directors in August 2017. She works as a consultant, Mentor and Board Director. She has chaired a range of NFP, University and Government boards, including: SANE Australia; The DAX Centre; Breast Cancer Network Australia, Legal Aid QLD and the Griffith Law School Visiting Committee. She is a Mentor with McCarthy Mentoring. She has also provided consultancy services on issues relating to conflict resolution, Aboriginal Affairs, Women’s Policy, the Arts and Local Government to local, state and federal governments. Ms O’Donnell served as Director General of three QLD Government Departments. Her original degree is in Social Work from QLD University. She is also a Fellow of the Australian Institute of Company Directors. She was awarded the Order of Australia in 2013. She has been diagnosed twice with breast cancer.

Professor Christobel Saunders AO, MB BS, FRCS, FRACS, FAAHMS is the James Stewart Chair of Surgery, the Head of the Department of Surgery at the University of Melbourne (Royal Melbourne Hospital precinct) and consultant surgeon in the Department of General Surgery at Royal Melbourne Hospital and the Peter MacCallum Cancer Institute. She is internationally recognised as one of Australia’s most prominent research-orientated cancer surgeons. She has substantially contributed to breast cancer research including clinical trials of new treatments, psychosocial, translational and health services research.

In recognition of her sustained career excellence and innovation, Christobel has been publicly acknowledged through numerous awards and honours including Order of Australia 2018, the Uccio Querci della Rovere Award (2018), WA Women’s Hall of Fame Inductee (2018), WA Scientist of the Year (2017) and Cancer Council WA career Achievement Award (2021). She has performed research for >30 years evaluating the efficacy and utility of therapy for early breast cancer.

In the past five years, Christobel has published over 200 peer-reviewed journal articles (two in The Lancet), six letters to the editor/editorials, two research reports, two book chapters and one book. She sits on the boards of a number of health and research organisations including as Vice-President for All.can International and on the boards of All.can Australia, Breast Cancer Trials, the Australian Centre for Value Based Health Care and PathWest. Christobel is closely involved in strategic planning and management of health and cancer services in Australia including being on the Medicare Review Advisory Committee, past President of the Cancer Council WA and Breast Surgical Society of ANZ, and past Advisory Council member of Cancer Australia. She was Inaugural Chair of the state Health Service Provider, PathWest Laboratory Medicine.

Professor Andrew Spillane was elected to the BCT Board in July 2021 and is a member of the Finance, Risk and Audit Committee. He is Professor of Surgical Oncology at The University of Sydney, Northern Clinical School. He specialises in the surgical management of breast cancer and melanoma. Professor Spillane is a senior VMO surgeon at the Mater North Sydney, Royal North Shore Hospital and North Shore Private Hospitals.

He is a member of the BCT Scientific Advisory Committee and immediate past BCT breast surgery Craft Group Lead. He is past President of BreastSurgANZ and a board member / Deputy Chair of Melanoma and Skin Cancer (MASC) Trials (formerly the ANZMTG). He is a member of the BCNA Medical Advisory Committee and Faculty Member of Melanoma Institute Australia. Professor Spillane is Breast sub-editor for the ANZ Journal of Surgery, and the Journal of Surgical Oncology and founding co-director of the University of Sydney’s Graduate Certificate in Advanced Breast Surgery.

Andrew’s research interests include neoadjuvant and surgical clinical trials, promoting involvement of surgeons in multidisciplinary clinical trials, issues around quality assurance in surgery, and safe introduction of new surgical techniques. He is involved in clinical and translational research on aspects of breast cancer and melanoma research including trial management committee of the multiple international trials and an active member of the International Neoadjuvant Melanoma Consortium. He has been an author on about 190 peer reviewed publications and co-authored 4 book chapters and chief investigator on multiple existing and recent NHMRC and MRFF grants.

Associate Professor Nicholas Wilcken was elected to the Breast Cancer Trials Board of Directors in July 2016. He was the Chair of the BCT’s Scientific Advisory Committee from 2011 to March 2017. Associate Professor Wilcken is the Director of Medical Oncology at the Crown Princess Mary Cancer Centre Westmead, and Associate Professor of Medicine at the University of Sydney. His clinical interests are mainly in breast cancer and his research interests include systematic reviews and breast cancer clinical trials. He is currently the Co-ordinating Editor of the Cochrane Collaboration’s Breast Cancer Group. He has been an invited expert panel member for previous St Gallen Early Breast Cancer Consensus Conferences in Switzerland and is a member of the Steering Committee of the Early Breast Cancer Trialists’ Collaborative Group, based in Oxford, UK.